Charles River Laboratories Debt/Equity Ratio 2010-2024 | CRL

Charles River Laboratories debt/equity ratio for the quarter ending September 30, 2024 was 0.61.

  • Charles River Laboratories average debt/equity ratio for 2023 was 0.8, a 23.81% decline from 2022.
  • Charles River Laboratories average debt/equity ratio for 2022 was 1.05, a 5.41% decline from 2021.
  • Charles River Laboratories average debt/equity ratio for 2021 was 1.11, a 4.31% decline from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

Charles River Laboratories Debt/Equity Ratio 2010-2024 | CRL

  • Charles River Laboratories average debt/equity ratio for 2023 was 0.8, a 23.81% decline from 2022.
  • Charles River Laboratories average debt/equity ratio for 2022 was 1.05, a 5.41% decline from 2021.
  • Charles River Laboratories average debt/equity ratio for 2021 was 1.11, a 4.31% decline from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
Elevance Health (ELV)$91.4B
Cencora (COR)$47.5B
DiDi Global (DIDIY)$23.3B
Natera (NTRA)$21.4B
ICON (ICLR)$16.1B
Viatris (VTRS)$15.6B
Avantor (AVTR)$13.4B
Revvity (RVTY)$13.4B
CochLear (CHEOY)$12.8B
BioMerieux (BMXMF)$12.7B
Solventum (SOLV)$11.6B
Medpace Holdings (MEDP)$9.8B
Doximity (DOCS)$9.6B
HealthEquity (HQY)$9B
Sonic Healthcare (SKHHY)$8.8B
Bausch + Lomb (BLCO)$6.9B
Life Times (LTH)$5.1B
Sotera Health (SHC)$3.9B
Organon (OGN)$3.8B
BrightSpring Health Services (BTSG)$3.2B
Surgery Partners (SGRY)$2.9B
PACS (PACS)$2.6B
Concentras Parent (CON)$2.6B
Ardent Health Partners (ARDT)$2.4B
Premier (PINC)$2.1B
Alignment Healthcare (ALHC)$2.1B
Ryman Healthcare (RYHTY)$2B
GeneDx Holdings (WGS)$2B
GoodRx Holdings (GDRX)$1.6B
Teladoc Health (TDOC)$1.5B